The U.S. Food and Drug Administration (FDA) has approved Roche’s Actemra/RoActemra (tocilizumab) subcutaneous injection for the treatment of giant cell arteritis (GCA), a chronic and severe autoimmune condition.
Roche noted in its press release that Actemra/RoActemra is the first therapy approved by the FDA for the treatment of adult patients with GCA. This is the sixth FDA approval for Actemra/RoActemra since the medicine was launched in 2010.
“Today’s FDA decision means people living with giant cell arteritis will, for the first time, have an FDA-approved treatment option for this debilitating disease,” said Sandra Horning, MD, Chief Medical Officer and Head of Global Product Development. “With no new treatments in more than 50 years, this approval could be transformational for people with GCA and for their physicians.”
The company said that the approval is based on the positive outcome of the Phase III GiACTA study evaluating Actemra/RoActemra in patients with GCA. The results showed that Actemra/RoActemra, initially combined with a six-month steroid (glucocorticoid) regimen, more effectively sustained remission through 52 weeks compared to placebo combined with a 26-week steroid taper and placebo combined with a 52-week steroid taper.